Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Moderna commences Phase 2 study of omicron-specific booster

By Brian Buntz | January 27, 2022

ModernaMere days after rivals Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) announced the launch of a study testing an omicron-based booster vaccine candidate, Moderna (NSDQ:MRNA) has announced its own trial of an omicron-specific vaccine.

The vaccine booster candidate, mRNA-1273.529, will be the subject of a Phase 2 study involving approximately 600 participants divided into two cohorts.

The first cohort in the trial will receive a dose of the mRNA-1273.529 after receiving a primary series of the COVID-19 vaccine mRNA-1273. The second cohort will receive a dose of mRNA-1273.529 after receiving a two-dose primary series and a 50-µg booster dose of the same vaccine.

The first cohort will receive a dose of mRNA-1273.529 at least six months after completion of a primary series. The second cohort will receive the mRNA-1273.529 vaccine candidate three months after receipt of a third dose.

The company is also considering including the omicron-specific vaccine candidate in its multivalent booster program.

The company had previously announced that a third dose of the mRNA-1273 appeared to result in a considerable increase in protection against the omicron variant. A 50-µg booster of the vaccine led to an approximately 37-fold increase in neutralizing antibody levels against omicron. A 100-µg booster led to a roughly 83-fold increase.

Moderna recently published neutralizing antibody data for the omicron variant in The New England Journal of Medicine.

Moderna also has a variety of COVID-19 vaccine candidates in its pipeline, including versions for the beta and delta variants as well as two multivalent candidates. In addition, the company is developing a next-generation refrigerator-stable COVID-19 vaccine known as mRNA-1283.

Moderna is also currently conducting a trial involving its mRNA-1273 vaccine in children aged 2 to 5 years. It expects to share data from that trial in March.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 vaccine, Moderna, Moderna COVID-19 vaccine, mRNA-1273, mRNA-1273.52, mRNA-1283
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Janssen
Janssen’s company group chairman dishes on growth strategy
Curebase
Curebase raises $40 million in Series B funding round 

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50